- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 15 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.2: 11 residues within 4Å:- Chain A: S.179, P.182, L.231, N.232, N.346, G.348, I.407, Q.408, V.414, S.415
- Ligands: NAG.27
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:V.414
- Hydrogen bonds: A:G.348, A:V.414, A:Q.408, A:Q.408
NAG-NAG-BMA-MAN-MAN.9: 11 residues within 4Å:- Chain G: S.179, P.182, L.231, N.232, N.346, G.348, I.407, Q.408, V.414, S.415
- Ligands: NAG.38
2 PLIP interactions:2 interactions with chain G- Hydrophobic interactions: G:V.414
- Hydrogen bonds: G:G.348, G:V.414, G:Q.408, G:Q.408
NAG-NAG-BMA-MAN-MAN.16: 11 residues within 4Å:- Chain M: S.179, P.182, L.231, N.232, N.346, G.348, I.407, Q.408, V.414, S.415
- Ligands: NAG.49
2 PLIP interactions:2 interactions with chain M- Hydrophobic interactions: M:V.414
- Hydrogen bonds: M:G.348, M:V.414, M:Q.408, M:Q.408
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.4: 12 residues within 4Å:- Chain A: N.265, T.267, H.299, N.301, S.381, I.383, R.412
- Chain C: I.104, F.105, G.106, V.107, V.108
2 PLIP interactions:2 interactions with chain C- Hydrophobic interactions: C:V.108
- Hydrogen bonds: C:V.108
NAG-NAG-BMA-MAN-MAN-MAN.11: 12 residues within 4Å:- Chain G: N.265, T.267, H.299, N.301, S.381, I.383, R.412
- Chain I: I.104, F.105, G.106, V.107, V.108
2 PLIP interactions:2 interactions with chain I- Hydrophobic interactions: I:V.108
- Hydrogen bonds: I:V.108
NAG-NAG-BMA-MAN-MAN-MAN.18: 12 residues within 4Å:- Chain M: N.265, T.267, H.299, N.301, S.381, I.383, R.412
- Chain O: I.104, F.105, G.106, V.107, V.108
2 PLIP interactions:2 interactions with chain O- Hydrophobic interactions: O:V.108
- Hydrogen bonds: O:V.108
- 33 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.22: 4 residues within 4Å:- Chain A: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.23: 5 residues within 4Å:- Chain A: V.144, R.162, L.163, I.164, N.167
Ligand excluded by PLIPNAG.24: 3 residues within 4Å:- Chain A: N.271, L.292, V.410
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: N.308, W.364
Ligand excluded by PLIPNAG.26: 4 residues within 4Å:- Chain A: Q.332, S.357, N.361
- Ligands: NAG-NAG.5
Ligand excluded by PLIPNAG.27: 4 residues within 4Å:- Chain A: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.2
Ligand excluded by PLIPNAG.28: 4 residues within 4Å:- Chain A: E.57, N.58
- Chain B: G.16, S.17
Ligand excluded by PLIPNAG.29: 4 residues within 4Å:- Chain A: N.204, T.206, S.244, I.247
Ligand excluded by PLIPNAG.30: 1 residues within 4Å:- Chain A: N.324
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain B: N.107, S.109
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain B: K.122, E.123, S.125, N.126
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain G: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.34: 5 residues within 4Å:- Chain G: V.144, R.162, L.163, I.164, N.167
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain G: N.271, L.292, V.410
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain G: N.308, W.364
Ligand excluded by PLIPNAG.37: 4 residues within 4Å:- Chain G: Q.332, S.357, N.361
- Ligands: NAG-NAG.12
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain G: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.9
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain G: E.57, N.58
- Chain H: G.16, S.17
Ligand excluded by PLIPNAG.40: 4 residues within 4Å:- Chain G: N.204, T.206, S.244, I.247
Ligand excluded by PLIPNAG.41: 1 residues within 4Å:- Chain G: N.324
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain H: N.107, S.109
Ligand excluded by PLIPNAG.43: 4 residues within 4Å:- Chain H: K.122, E.123, S.125, N.126
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain M: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.45: 5 residues within 4Å:- Chain M: V.144, R.162, L.163, I.164, N.167
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain M: N.271, L.292, V.410
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain M: N.308, W.364
Ligand excluded by PLIPNAG.48: 4 residues within 4Å:- Chain M: Q.332, S.357, N.361
- Ligands: NAG-NAG.19
Ligand excluded by PLIPNAG.49: 4 residues within 4Å:- Chain M: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.16
Ligand excluded by PLIPNAG.50: 4 residues within 4Å:- Chain M: E.57, N.58
- Chain N: G.16, S.17
Ligand excluded by PLIPNAG.51: 4 residues within 4Å:- Chain M: N.204, T.206, S.244, I.247
Ligand excluded by PLIPNAG.52: 1 residues within 4Å:- Chain M: N.324
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain N: N.107, S.109
Ligand excluded by PLIPNAG.54: 4 residues within 4Å:- Chain N: K.122, E.123, S.125, N.126
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Steichen, J.M. et al., A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science (2019)
- Release Date
- 2019-11-06
- Peptides
- HIV-1 Env BG505 MD64 N332-GT5 SOSIP gp120: AGM
HIV-1 Env BG505 MD64 N332-GT5 SOSIP gp41: BHN
BG18-like precursor HMP1 fragment antigen binding heavy chain: CIO
BG18-like precursor HMP1 fragment antigen binding light chain: DJP
base-binding RM20A3 fragment antigen binding heavy chain: EKQ
base-binding RM20A3 fragment antigen binding light chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AG
CM
JB
BH
DN
MC
HI
EO
OD
LJ
FP
PE
KK
GQ
QF
NL
IR
R
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 15 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 33 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Steichen, J.M. et al., A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science (2019)
- Release Date
- 2019-11-06
- Peptides
- HIV-1 Env BG505 MD64 N332-GT5 SOSIP gp120: AGM
HIV-1 Env BG505 MD64 N332-GT5 SOSIP gp41: BHN
BG18-like precursor HMP1 fragment antigen binding heavy chain: CIO
BG18-like precursor HMP1 fragment antigen binding light chain: DJP
base-binding RM20A3 fragment antigen binding heavy chain: EKQ
base-binding RM20A3 fragment antigen binding light chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AG
CM
JB
BH
DN
MC
HI
EO
OD
LJ
FP
PE
KK
GQ
QF
NL
IR
R